Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IIITerminatedNov 16, 2016Kamedis BIO-HERBAL DANDRUFF CARE THERAPEUTIC 2-STEP DANDRUFF CARE SYSTEM - Kamedis Bio-Herbal Dandruff Care...Subpotent Drug: Out of Specification assay values on stability for the active ingredient, zinc pyrithione.Taro Pharmaceuticals U.S.A., Inc. · D-0134-2017Class IITerminatedNov 16, 2016Transderm ScopDefective Delivery System; reports of damaged product that may alter the predicted release of scopolamine following transdermal application.Sandoz Inc · D-0133-2017Class IIITerminatedNov 16, 2016Estradiol 12.5 mg PelletSuperpotent and Subpotent drugsWells Pharmacy Network, LLC · D-0132-2017Class IITerminatedNov 16, 2016Testosterone 200 mg/Anastrazole 20mg PelletSuperpotent and Subpotent drugsWells Pharmacy Network, LLC · D-0131-2017Class IIITerminatedNov 16, 2016Estradiol 3 mg PelletSuperpotent and Subpotent drugsWells Pharmacy Network, LLC · D-0130-2017Class IIITerminatedNov 16, 2016Testosterone 12.5 mg PelletSuperpotent and Subpotent drugsWells Pharmacy Network, LLC · D-0129-2017Class IITerminatedNov 16, 2016Testosterone 60 mg/Anastrazole 4 mg PelletSuperpotent and Subpotent drugsWells Pharmacy Network, LLC · D-0128-2017Class IIITerminatedNov 16, 2016Testosterone CholesterolSuperpotent and Subpotent drugsWells Pharmacy Network, LLC · D-0127-2017Class IITerminatedNov 16, 2016Testosterone 200 mg/Anastrozole 9 mg PelletSuperpotent and Subpotent drugsWells Pharmacy Network, LLC · D-0126-2017Class IITerminatedNov 9, 2016Succinylcholine ChlorideLack of Assurance of Sterility: A portion of the batch quantity was compounded outside of the firm's process media validation.Pharmedium Services, LLC · D-0125-2017Class IITerminatedNov 9, 2016Sodium Chloride Ophthalmic SolutionSubpotent Drug: concentration of product is less than labeled amount.Akorn Inc · D-0124-2017Class IIITerminatedNov 9, 2016Gildess 24 FE 1.5/30Subpotent Drug; Ethinyl EstradiolPar Pharmaceutical, Inc. · D-0123-2017Class IIITerminatedNov 9, 2016Gildess FE 1.5/30Subpotent Drug; Ethinyl EstradiolPar Pharmaceutical, Inc. · D-0122-2017Class IIITerminatedNov 9, 2016Gildess FE 1/20Subpotent Drug; Ethinyl EstradiolPar Pharmaceutical, Inc. · D-0121-2017Class IIITerminatedNov 9, 2016Gildess 1/20Subpotent Drug; Ethinyl EstradiolPar Pharmaceutical, Inc. · D-0120-2017Class IIITerminatedNov 9, 2016Gildess 1.5/30Subpotent Drug; Ethinyl EstradiolPar Pharmaceutical, Inc. · D-0119-2017Class IIITerminatedNov 9, 2016Ramipril CapsulesLabeling: Incorrect or Missing Lot And/or Exp Date: Bottles labeled with the incorrect expiration date of 03/18 rather than 09/17.Actavis Laboratories, FL, Inc. · D-0118-2017Class IITerminatedNov 9, 2016Desoximetasone Cream USPFailed Stability Specifications: The subject lots exhibited OOS results for Homogeneity test (Moderate separation).Taro Pharmaceuticals, Inc. · D-0117-2017Class IITerminatedNov 9, 2016Desoximetasone Cream USPFailed Stability Specifications: The subject lots exhibited OOS results for Homogeneity test (Moderate separation).Taro Pharmaceuticals, Inc. · D-0116-2017Class IIITerminatedNov 2, 2016InvokametLabeling: Incorrect or Missing Package Insert - Xarelto prescribing information outserts may be affixed to the exterior of Invokamet bottles in place of the Invokamet...Janssen Ortho L.L.C. · D-0115-2017Class IITerminatedNov 2, 2016DIPYRIDAMOLE Tablets USPPresence of foreign tablets/capsules: 50 mg Persantine tablets were found in a 75 mg Persantine 100-count bottle and 50 mg Persantine tablet was found in a 100 count...Boehringer Ingelheim Pharmaceuticals, Inc. · D-0114-2017Class IITerminatedNov 2, 2016PersantinePresence of foreign tablets/capsules: 50 mg Persantine tablets were found in a 75 mg Persantine 100-count bottle and 50 mg Persantine tablet was found in a 100 count...Boehringer Ingelheim Pharmaceuticals, Inc. · D-0113-2017Class IITerminatedOct 26, 2016Trokendi XRSuperpotent Drug: Failure of assay specifications in the capsule.Supernus Pharmaceuticals, Inc. · D-0112-2017Class IIITerminatedOct 26, 2016PARICALCITOL CapsulesFailed Impurities/Degradation Specifications: out of specification test results for impurities during stability testing.Teva Pharmaceuticals USA · D-0111-2017Class IIITerminatedOct 26, 2016PARICALCITOL CapsulesFailed Impurities/Degradation Specifications: out of specification test results for impurities during stability testing.Teva Pharmaceuticals USA · D-0110-2017Class IIITerminatedOct 26, 2016PARICALCITOL CapsulesFailed Impurities/Degradation Specifications: out of specification test results for impurities during stability testing.Teva Pharmaceuticals USA · D-0109-2017Class IITerminatedOct 26, 2016Dream Body Advanced 400 mg 30 capsules in brown foil packetsMarketed without an approved NDA/ANDA: Undeclared sibutramine.Dream Body Weight Loss · D-0108-2017Class IITerminatedOct 26, 2016Dream Body 450 mg 30 capsules in a plastic screw on top bottleMarketed without an approved NDA/ANDA: Undeclared sibutramine.Dream Body Weight Loss · D-0107-2017Class IITerminatedOct 26, 2016Dream Body Extreme Gold 800 mg 30 capsules in a plastic screw on top bottleMarketed without an approved NDA/ANDA: Undeclared sibutramine.Dream Body Weight Loss · D-0106-2017Class ITerminatedOct 26, 2016CetylevDefective Container: Incomplete seal on blister packaging, leading to tablet swelling and enlarging due to effervescence process beginning as oxygen and moisture enter...Arbor Pharmaceuticals Inc. · D-0105-2017Class ITerminatedOct 26, 2016Super Samurai-XMarketed without an approved NDA/ANDA: FDA sample analyses revealed the presence of undeclared sildenafil and/or its analogs in products marketed as dietary supplementsSOS Telecom Inc. · D-0104-2017Class ITerminatedOct 26, 2016Ginseng Power-XMarketed without an approved NDA/ANDA: FDA sample analyses revealed the presence of undeclared sildenafil and/or its analogs in products marketed as dietary supplementsSOS Telecom Inc. · D-0103-2017Class ITerminatedOct 26, 2016Ninja-X, 4200 mgMarketed without an approved NDA/ANDA: FDA sample analyses revealed the presence of undeclared sildenafil and/or its analogs in products marketed as dietary supplementsSOS Telecom Inc. · D-0102-2017Class ITerminatedOct 26, 2016Tiger-X, 1200 mgMarketed without an approved NDA/ANDA: FDA sample analyses revealed the presence of undeclared sildenafil and/or its analogs in products marketed as dietary supplementsSOS Telecom Inc. · D-0101-2017Class IITerminatedOct 19, 2016TAZORACFailed Content Uniformity SpecificationsAllergan Sales, LLC · D-0100-2017Class IITerminatedOct 19, 2016TAZORACFailed Content Uniformity SpecificationsAllergan Sales, LLC · D-0099-2017Class IIITerminatedOct 19, 2016ZENATANEFailed Dissolution SpecificationsDr. Reddy's Laboratories, Inc. · D-0098-2017Class IITerminatedOct 19, 2016Marcaine 0.5%Lack of Assurance of Sterility and Subpotent Drug: defect in glass vial prevented stopper from forming a seal allowing water to ingress and dilute the product causing it...Hospira Inc., A Pfizer Company · D-0097-2017Class IITerminatedOct 19, 2016Marcaine 0.25%Lack of Assurance of Sterility and Subpotent Drug: defect in glass vial prevented stopper from forming a seal allowing water to ingress and dilute the product causing it...Hospira Inc., A Pfizer Company · D-0096-2017Class IIITerminatedOct 19, 2016mitoXANTRONE Injection USPFailed Impurities/Degradation Specifications: potential failure to meet the specification for Impurity D throughout shelf-life.Teva Pharmaceuticals USA · D-0095-2017